Our recent study demonstrated that combined ADMSCs and valsartan or combined ADMSCs and melatonin therapy effectively entreasured the residual renal function in CKD rat mainly through upregulating the PrPc involvement in promoting the PI3K/Akt/m-TOR signaling and cell proliferation [27]. The gene discussed is AKT1; the disease is chronic kidney disease.